WO2015144997A1 - Composition cosmetique et/ou dermatologique pour la coloration de la peau - Google Patents
Composition cosmetique et/ou dermatologique pour la coloration de la peau Download PDFInfo
- Publication number
- WO2015144997A1 WO2015144997A1 PCT/FR2015/000065 FR2015000065W WO2015144997A1 WO 2015144997 A1 WO2015144997 A1 WO 2015144997A1 FR 2015000065 W FR2015000065 W FR 2015000065W WO 2015144997 A1 WO2015144997 A1 WO 2015144997A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition according
- formula
- compound
- acid
- skin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/042—Gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/731—Cellulose; Quaternized cellulose derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/04—Preparations for care of the skin for chemically tanning the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
Definitions
- the invention relates to a cosmetic and / or dermatological composition for use in coloring the skin.
- Tanning by the solar radiation generates, in the superficial layers of the skin, an increase in melanin, which is not the case with current self-tanning products; this results in a significant difference in the colorations obtained by self-tanning products, even homogeneous, those obtained under the effect of solar radiation.
- melanocyte-stimulating hormone SSH
- melanosomes which are matured in melanocytes and transported in multiple melanocyte indentations (see Nature Reviews, Molecular Cell Biology, Vol.2, October 2001, pp. 1-11).
- the melanosomes thus transported are transferred to the keratinocytes of the skin, which allows the migration of melanin in the successive layers of the skin to the stratum corneum and a subsequent browning of the skin. It therefore appears that, in order to increase the browning of the skin, it is preferable to stimulate the natural production of melanin and to act on the transfer of melanosomes from the melanocytes to the keratinocytes.
- the implementation of a catanionic combination according to the patent application WO 2011/039379, in which the aforementioned sterol derivative is associated to a surfactant, the association between the two molecules being obtained by acid-base reaction and the asset constituting an amphiphilic counterion with therapeutic properties.
- the carrier / active association is linked by electrostatic interactions, which allows easy release of the active agent into the tissues and spreading of the cosmetic effect by a delay relative to the separation of the active ingredient.
- the carrier can play a triple role: facilitate the passage of the asset, have a clean cosmetic action on the skin cells and have a delay action for the release of the asset.
- the carrier / active assembly associates a positive ionization group of the active with the acid group of the carrier.
- the active agent may therefore be associated with the carrier by the substituent R 3 carried by the carbon 6 of the cholesterol skeleton of the compound of formula (I) defined below.
- the subject of the present invention is therefore a cosmetic composition that can be applied topically to brown the skin of a human subject, with or without irradiation with ultraviolet rays, characterized in that it contains, in a cosmetically transported vehicle. acceptable, an aqueous solution of at least one compound of formula (I):
- Ri represents a hydrogen atom or Ri 0 -CO, Rio representing H, CH 3 or C 2 H 5 ,
- R 2 represents a hydrogen atom or OH
- R 3 is X- (CH 2 ) n -Y, where n is an integer of 1 to 4, X is S, O or NH, and Y is NH 2 , imidazol-5-yl, indol-3-yl; , piperidine-2- yl, piperidin-3-yl, piperidin-4-yl, piperazin-2-yl, piperazin-3-yl, pyridin-2-yl, pyridin-3-yl or pyridin-4-yl,
- R 4 represents a hydrogen atom or OH in positio 20, 22, 24, 25, 26 or 27 on the core shown above to define the formula (I), OH being positioned so as to obtain an asymmetric center of conformation R or S, ⁇ and Z 2 represent the possibility of having between the carbons C7 and. C8, on the one hand, and the carbons C22 and C23, on the other hand, single or double bonds,
- Ti, T 2 , T 3 are, independently of one another, H or CH 3 in O or S, T is H, CH 3 or C 2 H 5 positioned to form an asymmetrical center of conformation R or S.
- the composition contains from 0.01 to 500 g / l of compound (s) of formula (I).
- the composition contains at least one browning compound other than the compound (s) of formula (I).
- the browning compound (s) it contains, independently of the compound (s) of formula (I), is dihydroxyacetone and / or Erythrulose and / or at least one water-soluble dye.
- the composition contains at least one activating compound for melanogenesis other than the compound (s) of formula (I) chosen from the group formed by the substrates of the biosynthesis of melanin and biological activators of melanogenesis capable of acting by stimulating melanin synthesis and / or melanosome transfer from melanocytes to keratinocytes.
- said activator (s) is (or are) chosen from the group formed by L-tyrosine, or its derivatives such as N-acetyl-L-tyrosine, L-dihydrophenylalanine, aliphatic diols such as propylene glycol, cyclic diols, adenosine-1 receptor agonists, adenosine-2 receptor agonists, ⁇ -hydroxy acids and their derivatives, ⁇ -hyroxyacids and their derivatives, retinoids or their derivatives, pro-opiomelanocortic peptides, ⁇ ' ⁇ -MSH or its analogs, MC1R receptor agonists, cAMP analogues, psoralens, activators of PAR-2 receptor activity.
- L-tyrosine or its derivatives such as N-acetyl-L-tyrosine, L-dihydrophenylalanine, aliphatic diols such as propylene glycol, cyclic
- the composition is applied to the skin in an amount of between 0.0001 and 100 mg / cm 2 / day of compound (s) of formula (I).
- the invention also proposes to improve the. transporting the compound (s) of formula (I) to the keratinocytes of the skin by associating with this compound (s) at least one acidic amphiphilic transporter (T), to constitute catanionic association complexes by electrostatic interactions.
- the composition therefore contains an ionic solution of catanionic association complexes, each association of which consists of a molecule of formula (I) and one or two molecules of an acidic amphiphilic transporter (T).
- a catanionic association is carried out by at least one acid-base reaction carried out between the acid group of a transporter (T) and an amino group of the substituent R 3 of the carbon in position 6 of the formula (I).
- the transporter (T) is a sugar-derived bolaforme surfactant comprising within its structure an acid function.
- the acid function of the transporter (T) is chosen from the group consisting of carboxylic acids COOH, sulfuric acid 0- SO 3 H, sulphonic acid SO 3 H, phosphoric acid OP (O) (R 5 0 ) OH, where R 5 is a C 1 -C 6 alkyl, phosphine O-P (O) R 6 OH and phosphinic chain P (O) R 6 OH where R 6 is H or a C 1 -C 6 alkyl chain .
- the sugar derivative is a monosaccharide or polysaccharide derivative.
- the sugar derivative contained in the composition is a glucose or lactose derivative.
- the acid derivative of sugar consists of a sugar structure to which is connected by a group H, a linear or branched aliphatic chain (CH 2 ) P , the opposite end of which at the sugar structure carries a acid group, p being an integer having a value of between 4 and 10.
- the ratio of the weight amounts A of compound (s) of formula (I) and B of the carrier (s) (T) is between 0.001 and 1000.
- the composition contains from 0.01 to 150 g of all the constituents A and B per liter of composition.
- the composition comprises at least one adjuvant taken from the group consisting of at least one thickener and / or a water-soluble dye and / or a perfume and / or an alcohol and / or a vitamin and / or an emulsifier, used alone or in a mixture with optionally a co-emulsifier, and / or an oil or other fatty substance and / or a preservative and / or an antioxidant and / or a bactericide.
- at least one adjuvant taken from the group consisting of at least one thickener and / or a water-soluble dye and / or a perfume and / or an alcohol and / or a vitamin and / or an emulsifier, used alone or in a mixture with optionally a co-emulsifier, and / or an oil or other fatty substance and / or a preservative and / or an antioxidant and / or a bactericide.
- the composition contains at least one chemical or physical solar filter, or a mixture of such filters.
- ⁇ the composition is packaged in nanocapsules or catanionic vesicles nanosized suspended in a liquid medium.
- the composition is packaged in the form of hydrogels, creams, lotions, emulsions or aerosols.
- FIG. 1 represents the IR spectrum corresponding to the product obtained in example 3;
- FIG. 2 represents the NMR spectrum corresponding to the product obtained in example 3;
- FIG. 3 illustrates the results obtained in example 5.
- FIG. 4 illustrates the results obtained in example 6
- FIGS. 5a, 5b, 5c show a visualization of melanosomes in treated cells according to Example 7;
- FIG. 6 shows the result of a treatment according to example 8 for the expression of the genes in the treated cells
- FIG. 7 shows the result of a treatment according to Example 9 as regards the modulation of proteins, this result being visualized by a "Western Blot” technique
- FIGS. 8 and 9 show the result of a treatment with compositions according to the invention on a reconstituted skin
- FIG. 10 shows the result of a treatment according to example 10 on the modulation of proteins involved in melanogenesis
- FIG. 11 shows the quantities of melanin synthesized on a reconstituted skin sample after application of a composition according to Examples 12 and 13, said quantities and skin samples being defined as described in Example 10.
- DDA dexadazol-4-yl
- Meta-chloro-peroxybenzoic acid (0.73 g, 4.25 mmol, purity 70-75% by weight) is dissolved in methylene chloride (10 ml) and added dropwise, with stirring, to a mixture of cholesterol (1 g, 2.5 mmol) dissolved in methylene chloride (25 ml). The agitation is maintained all night.
- the reaction mixture is washed with an aqueous solution of sodium sulphite (10% by weight) and sodium hydrogen carbonate (5% by weight) and a saturated solution of a mixture of sodium chloride and potassium chloride.
- the organic phase is dried over anhydrous magnesium sulfate. The evaporation under vacuum of the organic solvent makes it possible to obtain 0.7 g of white needles (yield 70%).
- the solution is pre-purified on a grafted silica cartridge ("sep-pack cartridge RP C18", 500 mg, Waters); the excess polyamine is removed by passing water on the cartridge (5 ml); the product is eluted with a mixture CH 3 CN 1 / H 2 0 1 (5 ml).
- the product obtained is first characterized by thin layer chromatography (methanol). Then, a high performance chromatography (HPLC) was carried out on a "Perkin-Elmer LC200 series" apparatus equipped with an "Ultrasep ES100RP10" column (particles of 6 ⁇ ), with a length of 250 mm and a diameter of 8 mm. manufactured by the company "Bishoff".
- step a) of Example 1 a mixture of sitosterol and campesterol (70/30 by weight). The same amine as in example 1, step b) is used for the reaction on the epoxysterol obtained.
- R 3 ⁇ 4 (300MHz, MeOD) ⁇ ppm: 1, 05-2, 15 (m, 10H, CH 2E, 2Y CH, CH 25, CH 2 £, ⁇ 2 ⁇ ); 2.17 (t, 2H, CH 2 - );
- the product obtained is a pale yellow powder; it is hereinafter called L7DDA since it consists of an L7 molecule associated with a DDA molecule.
- the NMR spectrum is provided in Figure 2; it shows the formation of the ion pair which associates an L7 molecule and a DDA molecule.
- the chemical shift of the CH 2 group in alpha to COOH carboxylic acid moiety is different from the alpha carboxylate group COO "in this example, CH 2 -COOH present a chemical shift of 2,17ppm, while CH 2 -COO " has a chemical shift of 2.21ppm.
- step b) causes the characteristic band of the carboxylic acid function to disappear between 1800 and 1650 cm -1 in favor of two new bands in the 1610-1550 cm -1 region. (asymmetric elongation of COO " (carboxylate group)) and 1450-1400 cm “ 1 (symmetrical elongation of COO " (carboxylate group).)
- Figure 1 the disappearance of the characteristic band of the carboxylic acid function at 1726 cm “1 and the appearance of bands of symmetrical and asymmetrical stretching of the carboxylate group respectively to 1549 cm" 1 and 1403 cm "1.
- CAC ritical Aggregation Concentration
- Example 3 The same process as that of step b) of Example 3 can be used to form an association complex between an acidic amphiphilic carrier according to Example 3a2) and any one of the compounds of formula (I) since all these compounds comprise at least one NH group allowing a bond with the acid function of the carrier.
- a mixture of complexes was obtained by combining the product of Example 2 with that of Example 3a2): this mixture was designated hereinafter under the name L7AF130.
- the carrier / active assembly associates a positive ionization group of the active with the acid group of the carrier.
- the active agent may therefore associate with the transporter by the substituent R 3 carried by the carbon 6 of the compound of formula (I).
- two L7 transporter molecules can be associated with two amino functions of the substituent R 3 . From the process for obtaining Example 3b, it is sufficient to mix, in water at room temperature, two equivalents of L7 molecule for one equivalent of the active agent, in the same way as described above. in example 3b. Again, the mixture is initially a suspension, but becomes a clear solution, which shows that the resulting complex, hereinafter referred to as (L7) 2 (AF130) or (L7) 2 (DDA) according to the active ingredient, is water-soluble .
- the cells are inoculated and are treated for 24 hours with the tested product or the vehicle used (ethanol) and with, as a positive control, exposure to a dose of ultraviolet radiation of 20 mJ / cm 2 .
- the results are provided in FIG. 4. It is seen that the tyrosinase activity in the cells is, when compared to the control, increased when the cells have been treated with a composition containing the DDA active, with or without an associated L7 transporter or containing the associated AF130 active for each molecule with two L7 carrier molecules. It is also seen that an increase in tyrosinase activity goes hand in hand with an increase in melanin synthesis in the cell.
- Healthy murine melanocytes were treated as shown in Example 6 using untreated or treated cells with ⁇ AF130 or ⁇ (L7) 2 AF130.
- the synthesis of melanin was visualized by a staining according to the DAPI technique: the nuclei of the fluorescent cells in blue and, in contrast, the melanosomes, which are visualized in black, are highlighted.
- Figure 5a corresponds to the visualization of untreated cells 5b in the display cells treated ⁇ of AF130 and 5c, visualization of cells treated with ⁇ of (L7) 2 AF130 is evident that the amount melanosomes and thus the melanin synthesis is considerably increased by a treatment according to Example 6 (comparison with Figure 5a).
- the DAPI technique is implemented as follows: the cells are seeded on slides previously sterilized by washing with ethanol; they are treated with the active molecule studied or with a vehicle used (ethanol). After 24h treatment, the cells are fixed with a solution of formaldehyde diluted to one tenth (3.7% by weight) in PBS, for 15 minutes, at room temperature. The formaldehyde is then removed and the cells are washed with PBS. ⁇ a DAPI solution at l / 500th the Mowiol (mounting solution) are deposited on a slide. The coverslip is placed on the drop, the cells to be between blade and coverslip. The slides are placed at 4 ° C for the night before being observed. For each sample, a snapshot in "DAPI" mode is performed, allowing only the visualization of the cores as well as the same snapshot in "visible” mode. The two shots are then superimposed.
- the cells are seeded and treated for 24 hours with the molecules whose action we want to study, that is to say here, with the DDA ( ⁇ ), on the one hand, and with the L7DDA (0.1 or 1 or 2.5 or 5 ⁇ ), on the other hand.
- the results were compared with ultraviolet-irradiated cells as in Example 6.
- Figure 6 shows the ordinate expression of genes corresponding to tyrosinase, TRP-1 and TRP-2.
- RNA is extracted from the cells.
- the melanocytes are treated for 24 hours with the active molecule or with the control agent.
- LmL of Trizol- 8 is added after 5 minutes at room temperature, the whole is recovered in an Eppendorf tube.
- 200 ⁇ l of CHCl 3 are added at 4 ° C.
- the Eppendorf tubes are manually shaken, inverted for 15 seconds, left for 5 minutes at room temperature, and then centrifuged at 16000 g at 4 ° C for 10 minutes.
- the colorless aqueous phase is isolated.
- 500 L of isopropanol (-20 ° C) are added.
- the Eppendorf tubes are manually shaken, inverted for 15 seconds, left for 15 minutes at room temperature, and then centrifuged at 16200 g at 4 ° C for 10 minutes. The supernatant is removed. The pellet is washed with 1 mL of 75% ethanol (-20 ° C). After centrifugation at 16000g at 4 ° C for 5 minutes, the supernatant is removed. After 10 min of drying, the pellet is taken up with 30 L of water without RNase. The quantity and purity of the RNAs is estimated spectrophotometrically (230, 260 and 280 nm).
- RT-qPCR is performed; in an Eppendorf tube, the following are introduced: ⁇ , reverse transcriptase, 4 ⁇ L of 5x reaction mixture "iScript®5x", the amount of water without RNase necessary to arrive at an overall volume of 20 / L and the corresponding volume at 1 g of RNA.
- the Eppendorf tubes are then vortexed, centrifuged for a few seconds and then placed in the thermal cycler (program: 5 minutes at 25 ° C., then 30 minutes at 42 ° C., then 5 minutes at 85 ° C. and then return at 4 ° C.).
- the reference genes are: glyceraldehyde 3-phosphate dehydrogenase and Cyclophilin A1.
- the genes of interest are Tyrosinase, TRP-1 and TRP-2.
- a mixture is prepared with RNase-free water, Sybr Green® and the corresponding primer.
- the cDNAs previously obtained are taken up with 18 C ⁇ L of water without RNase.
- Five ⁇ L of cDNA are introduced at the bottom of each well. 20 liters of mixture are introduced at the edge of each well.
- the plate is then covered with a sticky plastic and centrifuged at 4000 rpm until there is no bubble.
- the plate is then placed in the thermocycler: 95 ° C. for 3 minutes, followed by 50 cycles of dry amplification at 95 ° C. then one minute at 60 ° C. At the end of these 50 cycles, the melting curves are generated at 95 ° C for 1 min and 95 ° C for 10 sec (80 cycles). It is thus possible to show, in FIG. 6, the stimulation of the expression of genes for the various products studied. The numerical results obtained are given in the table below.
- DDA and L7DDA cell treatments provide results showing that the enzymes involved in melanogenesis are stimulated as much as with UV irradiation.
- Example 9 Effect on Modulation of Proteins Involved in Melanogenesis (Western Blot)
- the treatment to be studied is performed on healthy murine melanocytes.
- the treatments are carried out with the compound DDA at ⁇ and with the compounds L7DDA, (L7) 2 DDA and (L7) 2 AF130 at ⁇ also.
- the positive control is carried out with cells having received a UV radiation dose of 20mJ / cm 2 .
- the reference protein is actin (43KDa). After 24 hours of treatment, the cells are scraped in cold PBS (4 ° C.) and then centrifuged at 1500 rpm at 4 ° C. for 5 minutes. The supernatant is removed.
- samples are prepared for deposition on SDS-PAGE gel (samples prepared at 10 ⁇ L): 10 ⁇ L, ie 10 ⁇ g of proteins are deposited, for each sample.
- membranes After transferring the liquid phase freeze proteins on a membrane of polyvinylidene fluoride, membranes are incubated with the primary antibody of interest (Tyrosinase: l / 2000th, Actin: l / e 10000, TRP-2: l / 2000 e ), then with the secondary antibody directed against the gene of interest (in all cases, at 1/1000 e ), coupled HRP (horseradish proxidase). Finally, after a 5mn incubation with lml / ECL membrane (enhanced chemiluminescence), the membranes are revealed in a dark room. This information is identically used for carrying out the tests detailed in Example 11 below (results in FIG. 10).
- Example 10 Treatment on reconstituted skin
- the epidermis is changed medium every day before the treatment to be studied.
- the treatment consists in adding in the medium, twice a day for five days, ⁇ of the treatment product.
- the epidermis is isolated and placed in an Eppendorf tube with 400 ⁇ of a "Solvable" reagent (supplied by Perkin-Elmer), then heated at 100 ° C for 1h.
- the absorbance is measured at 490 nm.
- the brownings of the epidermis at the end of treatment are studied by histology by highlighting the melanin deposits in the treated epidermis.
- the tissues are placed in a solution of formaldehyde at 4% and then included in paraffin and cut. Fontana-Masson staining (silver-based silver nitrate method) evidence in black melanin deposits. Observation of the sections under an optical microscope makes it possible to obtain the snapshots of FIG.
- Example 11 Study of the modulation of different proteins involved in melanogenesis on a reconstituted skin model.
- Example 9 Details of the method used have already been provided in Example 9 (GP100: 1/500 e , TRP-1: 1/1000 e , Rab27a: 1/500 e ).
- results are shown in FIG. 10 and show that the tyrosinase and the proteins involved in melanogenesis TRP-1 and GP100 (key protein of the biogenesis of melanosomes) are more strongly stimulated by the treatment with a composition according to the invention than by UV exposure.
- Rab27a a protein involved in the transfer of melanosomes, from melanocytes to keratinocytes is more strongly stimulated by treatment with catanionic associations.
- Examples 12 to 22 describe compositions according to the invention used in application on reconstituted human skins such as those used in Examples 10 and 11.
- the compounds are, depending on the case, indicated in chemical names or INCI names (International Nomenclature of Cosmetic Ingredients) and the quantities indicated are percentages by weight (percentage in active ingredient for DDA and catanionic associations).
- the reconstituted skin models are treated twice daily for three days with 2 mg / cm 2 of the formulations described below (Examples 12 to 22). The results are shown in Figure 11.
- EXAMPLE 12 The composition, the formulation of which is given below, is a hydroalcoholic gel prepared as follows: water and ethanol are first mixed, hydroxypropylcellulose is introduced therein, stirred until dissolution is complete. then the other constituents are added with stirring.
- EXAMPLE 13 The composition, the formulation of which is given below, is a hydroalcoholic gel prepared and used as in Example 12:
- EXAMPLE 14 The composition, the formulation of which is given below, is a hydrogel prepared as in Example 12, excluding ethanol, which is absent in the formulation. Hydroxyethylcellulose (sold under the name
- Example 15 The composition, the formulation of which is given below, is a hydrogel prepared as in Example 14.
- EXAMPLE 16 The composition, the formulation of which is given below, is a hydrogel prepared as in Example 14.
- EXAMPLE 17 The composition, the formulation of which is given below, is a hydrogel prepared as in Example 14.
- EXAMPLE 18 The composition, the formulation of which is given below, is a hydrogel prepared as in Example 14.
- EXAMPLE 19 The composition, the formulation of which is given below, is a hydrogel prepared as in Example 14.
- Example 20 The composition, the formulation of which is given below, is an emulsion prepared as follows; An aqueous phase A is prepared:
- An oil phase B is prepared: Paraffin oil 7.5
- Coco caprylate (sold under the name
- a phase C is prepared
- Phase B is heated to 80 ° C and phase A is heated to the same temperature. Phase B is slowly introduced with rapid stirring into phase A. The mixture is homogenized and cooled with slow stirring: phase C is added when the temperature is below 40.degree.
- Example 21 The composition, the formulation of which is given below, is an emulsion prepared as follows; An aqueous phase A is prepared:
- An oil phase B is prepared:
- Coco caprylate (sold under the name
- phase C is prepared:
- Phase B is heated to 70 ° C and phase A is heated to the same temperature. Phase B is slowly introduced with rapid stirring into phase A. The mixture is homogenized and cooled with slow stirring. Phase C is added when the temperature is below 40 ° C.
- Example 22 The composition, the formulation of which is given below, is a dry oil prepared as follows:
- phase A is prepared:
- Cocoglycerides sold under the name
- phase B is prepared:
- Phase B is introduced into phase A with stirring and homogenized.
- the skin samples have a natural, tanned, homogeneous and durable color.
- the intensities of self-tanning effects are obtained by Fontana-Masson staining of histological sections and are summarized in the table below.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15714852.9A EP3122329A1 (fr) | 2014-03-28 | 2015-03-24 | Composition cosmetique et/ou dermatologique pour la coloration de la peau |
CA2943614A CA2943614A1 (fr) | 2014-03-28 | 2015-03-24 | Composition cosmetique et/ou dermatologique pour la coloration de la peau |
US15/300,122 US20170216179A1 (en) | 2014-03-28 | 2015-03-24 | Cosmetic and/or dermatological composition for colouring the skin |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1400746A FR3019039B1 (fr) | 2014-03-28 | 2014-03-28 | Composition cosmetique et/ou dermatologique pour la coloration de la peau |
FR1400746 | 2014-03-28 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2015144997A1 true WO2015144997A1 (fr) | 2015-10-01 |
WO2015144997A8 WO2015144997A8 (fr) | 2016-11-17 |
Family
ID=51225586
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2015/000065 WO2015144997A1 (fr) | 2014-03-28 | 2015-03-24 | Composition cosmetique et/ou dermatologique pour la coloration de la peau |
Country Status (5)
Country | Link |
---|---|
US (1) | US20170216179A1 (fr) |
EP (1) | EP3122329A1 (fr) |
CA (1) | CA2943614A1 (fr) |
FR (1) | FR3019039B1 (fr) |
WO (1) | WO2015144997A1 (fr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20200238534A1 (en) * | 2017-10-18 | 2020-07-30 | Zume, Inc. | On-demand robotic food assembly equipment, and related systems and methods |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003089449A2 (fr) | 2002-04-19 | 2003-10-30 | Institut National De La Sante Et De La Recherche Medicale | Composes aminoalkylsteroles avec activite anti-tumeur et neuroprotective |
US20090280074A1 (en) * | 2006-03-01 | 2009-11-12 | Svenja Gschwind | Use of glycyrrhetic acid and/or glycyrrhizin for producing cosmetic preparations for tanning the skin |
WO2011039379A1 (fr) | 2009-10-02 | 2011-04-07 | Pierre Fabre Dermo-Cosmetique | Transport cooperatif de principes actifs basiques par des molecules amphiphiles acides |
-
2014
- 2014-03-28 FR FR1400746A patent/FR3019039B1/fr not_active Expired - Fee Related
-
2015
- 2015-03-24 US US15/300,122 patent/US20170216179A1/en not_active Abandoned
- 2015-03-24 EP EP15714852.9A patent/EP3122329A1/fr not_active Withdrawn
- 2015-03-24 WO PCT/FR2015/000065 patent/WO2015144997A1/fr active Application Filing
- 2015-03-24 CA CA2943614A patent/CA2943614A1/fr not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003089449A2 (fr) | 2002-04-19 | 2003-10-30 | Institut National De La Sante Et De La Recherche Medicale | Composes aminoalkylsteroles avec activite anti-tumeur et neuroprotective |
US20090280074A1 (en) * | 2006-03-01 | 2009-11-12 | Svenja Gschwind | Use of glycyrrhetic acid and/or glycyrrhizin for producing cosmetic preparations for tanning the skin |
WO2011039379A1 (fr) | 2009-10-02 | 2011-04-07 | Pierre Fabre Dermo-Cosmetique | Transport cooperatif de principes actifs basiques par des molecules amphiphiles acides |
Non-Patent Citations (6)
Title |
---|
ANDO ET AL., J.LIPID RES., vol. 40, 1999, pages 1312 |
DE MÉDINA ET AL., J.MED.CHEM., vol. 52, 2009, pages 7765 |
DE MEDINA PHILIPPE ET AL: "Synthesis of new alkylaminooxysterols with potent cell differentiating activities: identification of leads for the treatment of cancer and neurodegenerative diseases", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 52, no. 23, 10 December 2009 (2009-12-10), pages 7765 - 7777, XP009131948, ISSN: 0022-2623, [retrieved on 20090922], DOI: 10.1021/JM901063E * |
JUNG ET AL., EXP. MOL. MED., vol. 33, 2001, pages 131 |
NATURE REVIEWS, MOLECULAR CELL BIOLOGY, vol. 2, October 2001 (2001-10-01), pages 1 - 11 |
TIANHONG PAN ET AL: "The Role of Alpha-Synuclein in Melanin Synthesis in Melanoma and Dopaminergic Neuronal Cells", PLOS ONE, vol. 7, no. 9, 1 January 2012 (2012-01-01), pages e45183, XP055153788, ISSN: 1932-6203, DOI: 10.1371/journal.pone.0045183 * |
Also Published As
Publication number | Publication date |
---|---|
FR3019039B1 (fr) | 2017-06-02 |
US20170216179A1 (en) | 2017-08-03 |
EP3122329A1 (fr) | 2017-02-01 |
FR3019039A1 (fr) | 2015-10-02 |
CA2943614A1 (fr) | 2015-10-01 |
WO2015144997A8 (fr) | 2016-11-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0586392B1 (fr) | Procede de separation d'un compose vegetal | |
FR3034626A1 (fr) | Solvant eutectique d'extraction, procede d'extraction par eutectigenese utilisant ledit solvant, et extrait issu dudit procede d'extraction. | |
CA2102689A1 (fr) | Nouveau derive de l'acide cafeique, l'oraposide, composition cosmetique ou pharmaceutique, notamment dermatologique le contenant | |
FR2923717A1 (fr) | Compositions de derives polyphenoliques stilbeniques et leurs applications pour lutter contre les pathologies et le veillissement des organismes vivants | |
FR2949065A1 (fr) | Complexe eclaircissant la peau, utilisation dudit complexe, composition cosmetique ou pharmaceutique comprenant ledit complexe et procede pour son application | |
FR3044226A1 (fr) | Extrait alcoolique de parties aeriennes de solidago virgaurea subsp. alpestris, son procede d'obtention, et composition cosmetique ou dermatologique le contenant | |
EP0318369B2 (fr) | Composition à base de phases lamellaires lipidiques hydratées ou de liposomes contenant de la tyrosine ou un dérivé de tyrosine et composition cosmétique ou pharmaceutique, notamment dermatologique, à activité pigmentante, l'incorporant | |
WO2011117547A1 (fr) | Oligosaccharide extrait d'halymenia durvillaei, procede pour preparer un tel oligosaccharide et son utilisation cosmetique | |
EP2114387B1 (fr) | Utilisation de compositions comprenant au moins une lignane et/ou neolignane pour moduler le taux de testosterone | |
FR3026011A1 (fr) | Composition contenant au moins un inhibiteur de certaines chimiokines, son procede d'obtention et son utilisation dermocosmetique pharmaceutique | |
WO2015144997A1 (fr) | Composition cosmetique et/ou dermatologique pour la coloration de la peau | |
EP3579929B1 (fr) | Extraits de la lianemarsdenia cundurango | |
CN110615826A (zh) | 新型化合物、包含其的化妆料组合物及药学组合物 | |
WO2002058664A1 (fr) | Utilisation d'un isothiocyanate, d'un thiocyanate ou de leur melange en tant que depigmentant | |
EP1566168B1 (fr) | Compositions dermo-cosmétiques dépigmentantes et leur utilisation | |
FR3046932A1 (fr) | Preparation de vesicules multilamellaires, et preparation externe et cosmetique la comprenant | |
FR3059236A1 (fr) | Extraits de plantes du genre tagetes et leurs utilisations | |
CA2256947C (fr) | Composition depigmentante destinee a l'eclaircissement de la peau et au traitement des taches pigmentaires | |
WO2003000208A1 (fr) | Composition a usage topique comprenant un produit cytotoxique | |
FR3032115B1 (fr) | Composition comprenant une association de niosomes et de derive c-glycoside, d'extrait de crocus sativus et/ou d'extrait de fleur de crocus sativus, pour reguler la pigmentation cutanee | |
JP6295245B2 (ja) | 色素沈着阻害剤としてのリケステリン酸およびその誘導体 | |
FR2971711A1 (fr) | Composition cosmetique comprenant un extrait de petit epeautre en tant qu'agent activateur de la synthese des proteines de la matrice extracellulaire | |
WO2016046457A1 (fr) | Utilisation dermocosmetique ou pharmaceutique d'une composition contenant au moins un inhibiteur de certaines cytokines chimio-attractantes | |
JP2022105049A (ja) | 3-ヒドロキシシクロペンチル酢酸から誘導される新規化合物の合成方法 | |
FR3027797A1 (fr) | Utilisation de derives d'acide salicylique lipophiles |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15714852 Country of ref document: EP Kind code of ref document: A1 |
|
DPE2 | Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2943614 Country of ref document: CA |
|
REEP | Request for entry into the european phase |
Ref document number: 2015714852 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2015714852 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15300122 Country of ref document: US |